Top

World Journal of Urology

Published in:

01-12-2013 | Topic Paper

Improved performance of SPECT-CT In-111 capromab pendetide by correlation with diffusion-weighted magnetic resonance imaging for identifying metastatic pelvic lymphadenopathy in prostate cancer

Authors: Andrew D. Hardie, William J. Rieter, Marques L. Bradshaw, Leonie L. Gordon, Matthew A. Young, Thomas E. Keane

Published in: World Journal of Urology | Issue 6/2013

Abstract

Purpose

To preliminarily evaluate the potential for an improvement in diagnostic performance by a combined interpretation of In-111 capromab pendetide single photon emission computed tomography (SPECT) including computed tomography (CT) image fusion with magnetic resonance diffusion-weighted imaging (MR-DWI) for identifying prostate cancer in pelvic lymph nodes thru correlation with histopathology.

Materials and methods

This institutional approved, retrospective study identified patients with available histopathology of lymph nodes removed at the time of radical prostatectomy and who had undergone staging with In-111 capromab pendetide SPECT-CT and/or pelvic MRI (including DWI). The performance of In-111 capromab pendetide SPECT for identifying malignant lymph nodes was assessed. Subsequently, a combined reading of In-111 capromab pendetide SPECT and prostate MRI with DWI was performed and the performance assessed.

Results

18 patients underwent In-111 capromab pendetide SPECT-CT. Of these, 12 patients had also undergone imaging with MR-DWI. In-111 capromab pendetide SPECT-CT had a sensitivity of 40.0 % and specificity of 96.7 % for identification of malignant lymph nodes. However, In-111 capromab pendetide SPECT-CT combined with MRI with DWI had a sensitivity of 88.9 % and specificity of 98.5 %.

Conclusions

The addition of MR-DWI to the interpretation of In-111 capromab pendetide SPECT-CT may increase the sensitivity for detecting malignant lymph nodes in prostate cancer. Future prospective evaluation of combined In-111 capromab pendetide SPECT-CT and MR-DWI is indicated and may improve clinical evaluation of nodal disease in prostate cancer.

Gervasi LA, Mata J, Easley JD et al (1989) Prognostic significance of lymph nodal metastases in prostate cancer. J Urol 142(2 Pt 1):332–336PubMed

Heidenreich A, Varga Z, Von Knobloch R (2002) Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis. J Urol 167(4):1681–1686PubMedCrossRef

Briganti A, Larcher A, Abdollah F et al (2012) Updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection: the essential importance of percentage of positive cores. Eur Urol 61(3):480–487PubMedCrossRef

Briganti A, Blute ML, Eastham JH et al (2009) Pelvic lymph node dissection in prostate cancer. Eur Urol 55(6):1251–1265PubMedCrossRef

Briganti A, Abdollah F, Nini A, Suardi N, Gallina A, Capitanio U, Bianchi M, Tutolo M, Passoni NM, Salonia A, Colombo R, Freschi M, Rigatti P, Montorsi F (2012) Performance characteristics of computed tomography in detecting lymph node metastases in contemporary patients with prostate cancer treated with extended pelvic lymph node dissection. Eur Urol 61(6):1132–1138 Epub 2011 Nov 12PubMedCrossRef

Hovels AM, Heesakkers RA, Adang EM et al (2008) The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clin Radiol 63(4):387–395PubMedCrossRef

Bander NH (2006) Technology insight: monoclonal antibody imaging of prostate cancer. Nat Clin Pract Urol 3:216–225PubMedCrossRef

Horoszewicz JS, Kawinski E, Murphy GP (1987) Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res 7:927–935PubMed

Troyer JK, Beckett ML, Wright GL (1997) Location of prostate-specific membrane antigen in the LNCaP prostate carcinoma cell line. Prostate 30:232–242PubMedCrossRef

10.

Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C (1997) Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 3:81–85PubMed

11.

Wright GL Jr, Grob BM, Haley C et al (1996) Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology 48:326–334PubMedCrossRef

12.

Sweat SD, Pacelli A, Murphy GP, Bostwick DG (1998) Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology 52:637–640PubMedCrossRef

13.

Wynant GE, Murphy GP, Horoszewicz JS et al (1991) Immunoscintigraphy of prostatic cancer: preliminary results with 111In-labeled monoclonal antibody 7E11-C5.3 (CYT-356). Prostate 18:229–241PubMedCrossRef

14.

Manyak MJ, Hinkle GH, Olsen JO et al (1999) Immunoscintigraphy with indium-111-capromab pendetide: evaluation before definitive therapy in patients with prostate cancer. Urology 54:1058–1063PubMedCrossRef

15.

Schettino CJ, Kramer EL, Noz ME, Taneja S, Padmanabhan P, Lepor H (2004) Impact of fusion of indium-111 capromab pendetide volume data sets with those from MRI or CT in patients with recurrent prostate cancer. Am J Roentgenol 183:519–524CrossRef

16.

Rieter WJ, Keane TE, Ahlman MA, Ellis CT, Spicer KM, Gordon LL (2011) Diagnostic performance of In-111 capromab pendetide SPECT/CT in localized and metastatic prostate cancer. Clin Nucl Med 36(10):872–878PubMedCrossRef

17.

Wesbey GE, Moseley ME, Ehman RL (1984) Translational molecular self-diffusion in magnetic resonance imaging. II. Measurement of the self-diffusion coefficient. Invest Radiol 19(6):491–498PubMedCrossRef

18.

Abdel Razek AA, Soliman NY, Elkhamary S, Alsharaway MK, Tawfik A (2006) Role of diffusion-weighted MR imaging in cervical lymphadenopathy. Eur Radiol 16(7):1468–1477PubMedCrossRef

19.

Holzapfel K, Duetsch S, Fauser C, Eiber M, Rummeny EJ, Gaa J (2009) Value of diffusion-weighted MR imaging in the differentiation between benign and malignant cervical lymph nodes. Eur J Radiol 72(3):381–387PubMedCrossRef

20.

Sumi M, Sakihama N, Sumi T et al (2003) Discrimination of metastatic cervical lymph nodes with diffusion-weighted MR imaging in patients with head and neck cancer. AJNR Am J Neuroradiol 24(8):1627–1634PubMed

21.

King AD, Ahuja AT, Yeung DK et al (2007) Malignant cervical lymphadenopathy: diagnostic accuracy of diffusion-weighted MR imaging. Radiology 245(3):806–813PubMedCrossRef

22.

Kim JK, Kim KA, Park BW, Kim N, Cho KS (2008) Feasibility of diffusion-weighted imaging in the differentiation of metastatic from nonmetastatic lymph nodes: early experience. J Magn Reson Imaging 28(3):714–719PubMedCrossRef

23.

Thoeny HC, Triantafyllou M, Birkhaeuser FD et al (2009) Combined ultrasmall superparamagnetic particles of iron oxide-enhanced and diffusion-weighted magnetic resonance imaging reliably detect pelvic lymph node metastases in normal-sized nodes of bladder and prostate cancer patients. Eur Urol 55(4):761–769PubMedCrossRef

24.

Beer AJ, Eiber M, Souvatzoglou M et al (2011) Restricted water diffusibility as measured by diffusion-weighted MR imaging and choline uptake in (11)C-choline PET/CT are correlated in pelvic lymph nodes in patients with prostate cancer. Mol Imaging Biol 13(2):352–361PubMedCrossRef

25.

Budiharto T, Joniau S, Lerut E et al (2011) Prospective evaluation of 11C-choline positron emission tomography/computed tomography and diffusion-weighted magnetic resonance imaging for the nodal staging of prostate cancer with a high risk of lymph node metastases. Eur Urol 60(1):125–130PubMedCrossRef

26.

Mattei A, Danuser H (2011) Contemporary imaging analyses of pelvic lymph nodes in the prostate cancer patient. Curr Opin Urol 21(3):211–218PubMedCrossRef

Title: Improved performance of SPECT-CT In-111 capromab pendetide by correlation with diffusion-weighted magnetic resonance imaging for identifying metastatic pelvic lymphadenopathy in prostate cancer
Authors: Andrew D. Hardie
William J. Rieter
Marques L. Bradshaw
Leonie L. Gordon
Matthew A. Young
Thomas E. Keane
Publication date: 01-12-2013
Publisher: Springer Berlin Heidelberg
Published in: World Journal of Urology / Issue 6/2013
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-013-1079-2

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Improved performance of SPECT-CT In-111 capromab pendetide by correlation with diffusion-weighted magnetic resonance imaging for identifying metastatic pelvic lymphadenopathy in prostate cancer

Abstract

Purpose

Materials and methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Materials and methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 6/2013

Efficacy of antibiotic prophylaxis in patients undergoing cystoscopy: a randomized clinical trial

Is stone diameter a variable in the decision process of employing a ureteral stent in patients undergoing uncomplicated ureterorenoscopy and associated intracorporeal lithotripsy?

Shock wave lithotripsy versus ureteroscopy for ureteral calculi: a prospective assessment of patient-reported outcomes

Comparative proteomic study between human normal motility sperm and idiopathic asthenozoospermia

Salvage radical prostatectomy as management of locally recurrent prostate cancer: outcomes and complications

Robotic retroperitoneal partial nephrectomy